Role of diet in patients with acute-on-chronic liver failure with poor muscle mass and functio

Not Applicable

Completed

• Conditions: Health Condition 1: K721- Chronic hepatic failureHealth Condition 2: K740- Hepatic fibrosis

• Registration Number: CTRI/2022/01/039735
• Lead Sponsor: Post Graduate Institute of Medical Education and Research PGIMER

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2022-09-05
• Last Update Posted: 6 February 2023

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 70

Inclusion Criteria

A. Age more than 18 years and less than 75 years

B. Patients with a confirmed diagnosis of Acute-on-chronic liver failure by APASL criteria

APASL ACLF defined by serum bilirubin more than and equal to 5 mg/dl & coagulopathy (INR more than equal to 1.5 or PT less than 40%), complicated within 4 weeks by ascites and/or encephalopathy in a patient with chronic liver disease

C. Presence of frailty

Exclusion Criteria

1. Patients with AARC score more than 10

2. Patients with MELD score more than 30

3. Obese patient (BMI more than 25kg/m2)

4. Patients with active malignancy, hepatocellular carcinoma and, the end-stage renal disease.

5. Active alcohol abuse at the time of enrollment

6. Patients having prior study enrollment or enrollment in another conflicting study

7. Patients, who are not willing to participate in the study, will be excluded.

8. Patients who are participating in other clinical trials within past 3 months

9. Patients who has an active evidence of infection

10. Patients who had acute organic brain disease in the past 6 months

11. Patients who have severe hemodynamic instability, serious heart disease, severe bradycardia, or tachycardia at rest

12. Patients having renal failure (creatinine clearance rate less than and equal to 60 mL/min/1.73 m2)

13. Patients who are not able to perform the strength exercise; severe cognitive impairment (Mini-Mental State Examination less than and equal to 17), overt hepatic encephalopathy, or patients who had physical disability)

Study & Design

• Study Type: Interventional
• Study Design: Not specified